NEUROPACE, INC. Royalty Expense
NEUROPACE, INC. (NPCE) reported Royalty Expense of $400.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2023-03-02
- NEUROPACE, INC. royalty expense for fiscal 2022 was $400.00K, a 20.00% decline from fiscal 2021.
- NEUROPACE, INC. royalty expense for fiscal 2021 was $500.00K, a 25.00% increase from fiscal 2020.
- NEUROPACE, INC. royalty expense for fiscal 2020 was $400.00K.
| Period end | Royalty Expense 12 month |
|---|---|
| 2022-12-31 | $400.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $500.00K 10-K · filed 2023-03-02 |
| 2020-12-31 | $400.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |